AG˹ٷ

STOCK TITAN

[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Fulgent Genetics (FLGT) Form 4: Chief Scientific Officer Hanlin Gao satisfied tax-withholding liabilities from vested RSUs by allowing the company to withhold 1,642 common shares on 07/26/2025 at $18.37 each (transaction code F). Because the shares were retained by the issuer rather than sold on the open market, the transaction is administrative and does not signal active insider selling. Following the withholding, Gao’s direct holdings stand at 959,639 shares, a reduction of roughly 0.2%.

No derivative securities were exercised or disposed of, and no new shares were acquired. Given the small size relative to Gao’s total stake and FLGT’s public float, the filing has negligible impact on ownership structure or market supply.

Fulgent Genetics (FLGT) Modulo 4: Il Chief Scientific Officer Hanlin Gao ha soddisfatto le obbligazioni fiscali derivanti da RSU maturate consentendo all'azienda di trattenere 1.642 azioni ordinarie il 26/07/2025 al prezzo di 18,37 dollari ciascuna (codice transazione F). Poiché le azioni sono state trattenute dall'emittente anziché vendute sul mercato aperto, la transazione è di natura amministrativa e non indica una vendita attiva da parte dell'insider. Dopo questa operazione, la partecipazione diretta di Gao ammonta a 959.639 azioni, una riduzione di circa lo 0,2%.

Non sono stati esercitati o ceduti titoli derivati e non sono state acquisite nuove azioni. Considerata la dimensione ridotta rispetto alla partecipazione totale di Gao e al flottante pubblico di FLGT, la comunicazione ha un impatto trascurabile sulla struttura proprietaria o sull'offerta di mercato.

Fulgent Genetics (FLGT) Formulario 4: El Director Científico Hanlin Gao cumplió con las obligaciones fiscales derivadas de RSU adquiridas permitiendo que la empresa retuviera 1,642 acciones comunes el 26/07/2025 a $18.37 cada una (código de transacción F). Dado que las acciones fueron retenidas por el emisor en lugar de venderse en el mercado abierto, la transacción es administrativa y no indica una venta activa por parte del insider. Tras esta retención, las participaciones directas de Gao son de 959,639 acciones, una reducción de aproximadamente 0.2%.

No se ejercieron ni dispusieron valores derivados, ni se adquirieron nuevas acciones. Considerando el tamaño reducido en relación con la participación total de Gao y el flotante público de FLGT, la presentación tiene un impacto insignificante en la estructura de propiedad o en la oferta del mercado.

Fulgent Genetics (FLGT) Form 4: 최고 과학 책임� 한린 가�(Hanlin Gao)� 취득� RSU� 대� 세금 원천징수 의무� 충족하기 위해 2025� 7� 26� 회사가 보통� 1,642주를 주당 18.37달러� 원천징수하도� 허용했습니다(거래 코드 F). 주식� 공개 시장에서 매도� 것이 아니� 발행자가 보유했기 때문� � 거래� 행정� 성격이며 내부자의 적극적인 매도� 의미하지 않습니다. 원천징수 � 가오의 직접 보유 주식은 959,639�� � 0.2% 감소했습니다.

파생 증권은 행사되거� 처분되지 않았으며, 새로� 주식� 취득하지 않았습니�. 가오의 � 지� � FLGT� 공모 주식수에 비해 규모가 작기 때문� 이번 신고� 소유 구조� 시장 공급� 미미� 영향� 미칩니다.

Fulgent Genetics (FLGT) Formulaire 4 : Le Directeur Scientifique Hanlin Gao a réglé ses obligations fiscales liées aux RSU acquises en permettant à la société de retenir 1 642 actions ordinaires le 26/07/2025 au prix de 18,37 $ chacune (code transaction F). Comme les actions ont été conservées par l'émetteur et non vendues sur le marché ouvert, la transaction est administrative et ne signale pas une vente active par un initié. Après cette retenue, la détention directe de Gao s'élève à 959 639 actions, soit une diminution d'environ 0,2 %.

Aucun titre dérivé n'a été exercé ou cédé, et aucune nouvelle action n'a été acquise. Étant donné la faible taille de l'opération par rapport à la participation totale de Gao et au flottant public de FLGT, cette déclaration a un impact négligeable sur la structure de propriété ou l'offre sur le marché.

Fulgent Genetics (FLGT) Formular 4: Chief Scientific Officer Hanlin Gao erfüllte Steuerabzugsverpflichtungen aus erworbenen RSUs, indem er dem Unternehmen erlaubte, am 26.07.2025 1.642 Stammaktien zu je 18,37 USD einzubehalten (Transaktionscode F). Da die Aktien vom Emittenten einbehalten und nicht auf dem freien Markt verkauft wurden, handelt es sich um eine administrative Transaktion, die keinen aktiven Insider-Verkauf signalisiert. Nach dem Einbehalt hält Gao direkt 959.639 Aktien, was einer Reduzierung von etwa 0,2 % entspricht.

Es wurden keine Derivate ausgeübt oder veräußert, und es wurden keine neuen Aktien erworben. Aufgrund der geringen Größe im Verhältnis zu Gaos Gesamtanteil und dem öffentlichen Streubesitz von FLGT hat die Meldung keine nennenswerten Auswirkungen auf die Eigentümerstruktur oder das Marktangebot.

Positive
  • None.
Negative
  • Insider net disposition: 1,642 shares were removed from beneficial ownership, marginally diluting insider stake, albeit for tax purposes.

Insights

TL;DR: Routine share withholding for taxes; immaterial ownership change—neutral market impact.

The code F disposition reflects automatic withholding tied to previously disclosed RSU vesting from the 2022 Fulgent Pharma merger. Such transactions do not involve cash proceeds or open-market activity and are common for tax compliance. Gao retains nearly one million shares, preserving significant insider alignment. The 1,642-share reduction represents less than 1 day of FLGT’s average volume and should not affect liquidity, valuation, or perceived insider confidence.

Fulgent Genetics (FLGT) Modulo 4: Il Chief Scientific Officer Hanlin Gao ha soddisfatto le obbligazioni fiscali derivanti da RSU maturate consentendo all'azienda di trattenere 1.642 azioni ordinarie il 26/07/2025 al prezzo di 18,37 dollari ciascuna (codice transazione F). Poiché le azioni sono state trattenute dall'emittente anziché vendute sul mercato aperto, la transazione è di natura amministrativa e non indica una vendita attiva da parte dell'insider. Dopo questa operazione, la partecipazione diretta di Gao ammonta a 959.639 azioni, una riduzione di circa lo 0,2%.

Non sono stati esercitati o ceduti titoli derivati e non sono state acquisite nuove azioni. Considerata la dimensione ridotta rispetto alla partecipazione totale di Gao e al flottante pubblico di FLGT, la comunicazione ha un impatto trascurabile sulla struttura proprietaria o sull'offerta di mercato.

Fulgent Genetics (FLGT) Formulario 4: El Director Científico Hanlin Gao cumplió con las obligaciones fiscales derivadas de RSU adquiridas permitiendo que la empresa retuviera 1,642 acciones comunes el 26/07/2025 a $18.37 cada una (código de transacción F). Dado que las acciones fueron retenidas por el emisor en lugar de venderse en el mercado abierto, la transacción es administrativa y no indica una venta activa por parte del insider. Tras esta retención, las participaciones directas de Gao son de 959,639 acciones, una reducción de aproximadamente 0.2%.

No se ejercieron ni dispusieron valores derivados, ni se adquirieron nuevas acciones. Considerando el tamaño reducido en relación con la participación total de Gao y el flotante público de FLGT, la presentación tiene un impacto insignificante en la estructura de propiedad o en la oferta del mercado.

Fulgent Genetics (FLGT) Form 4: 최고 과학 책임� 한린 가�(Hanlin Gao)� 취득� RSU� 대� 세금 원천징수 의무� 충족하기 위해 2025� 7� 26� 회사가 보통� 1,642주를 주당 18.37달러� 원천징수하도� 허용했습니다(거래 코드 F). 주식� 공개 시장에서 매도� 것이 아니� 발행자가 보유했기 때문� � 거래� 행정� 성격이며 내부자의 적극적인 매도� 의미하지 않습니다. 원천징수 � 가오의 직접 보유 주식은 959,639�� � 0.2% 감소했습니다.

파생 증권은 행사되거� 처분되지 않았으며, 새로� 주식� 취득하지 않았습니�. 가오의 � 지� � FLGT� 공모 주식수에 비해 규모가 작기 때문� 이번 신고� 소유 구조� 시장 공급� 미미� 영향� 미칩니다.

Fulgent Genetics (FLGT) Formulaire 4 : Le Directeur Scientifique Hanlin Gao a réglé ses obligations fiscales liées aux RSU acquises en permettant à la société de retenir 1 642 actions ordinaires le 26/07/2025 au prix de 18,37 $ chacune (code transaction F). Comme les actions ont été conservées par l'émetteur et non vendues sur le marché ouvert, la transaction est administrative et ne signale pas une vente active par un initié. Après cette retenue, la détention directe de Gao s'élève à 959 639 actions, soit une diminution d'environ 0,2 %.

Aucun titre dérivé n'a été exercé ou cédé, et aucune nouvelle action n'a été acquise. Étant donné la faible taille de l'opération par rapport à la participation totale de Gao et au flottant public de FLGT, cette déclaration a un impact négligeable sur la structure de propriété ou l'offre sur le marché.

Fulgent Genetics (FLGT) Formular 4: Chief Scientific Officer Hanlin Gao erfüllte Steuerabzugsverpflichtungen aus erworbenen RSUs, indem er dem Unternehmen erlaubte, am 26.07.2025 1.642 Stammaktien zu je 18,37 USD einzubehalten (Transaktionscode F). Da die Aktien vom Emittenten einbehalten und nicht auf dem freien Markt verkauft wurden, handelt es sich um eine administrative Transaktion, die keinen aktiven Insider-Verkauf signalisiert. Nach dem Einbehalt hält Gao direkt 959.639 Aktien, was einer Reduzierung von etwa 0,2 % entspricht.

Es wurden keine Derivate ausgeübt oder veräußert, und es wurden keine neuen Aktien erworben. Aufgrund der geringen Größe im Verhältnis zu Gaos Gesamtanteil und dem öffentlichen Streubesitz von FLGT hat die Meldung keine nennenswerten Auswirkungen auf die Eigentümerstruktur oder das Marktangebot.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Xie Jian

(Last) (First) (Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CA 91731

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and COO
3. Date of Earliest Transaction (Month/Day/Year)
07/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/26/2025 F 4,352(1) D $18.37 367,144 D
Common Stock 220,816 I By Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
/s/ Paul Kim as Attorney-in-Fact 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many FLGT shares did Chief Scientific Officer Hanlin Gao dispose of?

A total of 1,642 shares were withheld by the company on 07/26/2025.

Was the transaction an open-market sale?

No. The code F designation shows shares were withheld by the issuer solely to cover tax obligations.

What price was used for the share withholding?

The shares were valued at $18.37 each, the fair-market price on the transaction date.

How many FLGT shares does Hanlin Gao now own?

After the transaction, Gao holds 959,639 common shares directly.

Does this Form 4 filing materially affect Fulgent Genetics� share float?

The 1,642-share reduction is immaterial relative to the company’s float and average trading volume.
Fulgent Genetics

NASDAQ:FLGT

FLGT Rankings

FLGT Latest News

FLGT Latest SEC Filings

FLGT Stock Data

532.46M
20.27M
32.8%
56.57%
4.47%
Diagnostics & Research
Services-medical Laboratories
United States
EL MONTE